<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>大叔快评 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-12T11:19:26+08:00</updated>
  <subtitle>肿瘤学临床研究及制药企业研发评述</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>Keytruda获得中国头颈部鳞状细胞癌一线适应症</title>
    <updated>2020-12-12T10:06:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/ZaYp_PQrwlAYIpzVqPRa6g</id>
    <link href="https://mp.weixin.qq.com/s/ZaYp_PQrwlAYIpzVqPRa6g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>三里路 上下天涯</title>
    <updated>2020-12-11T23:14:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/R4unT8NBzjdL8SkQ-Gz_Cw</id>
    <link href="https://mp.weixin.qq.com/s/R4unT8NBzjdL8SkQ-Gz_Cw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020ASH好声音 |【冯茹教授点评】ECHELON-2研究5年随访结果：BV+CHP对比CHOP一线治疗CD30+PTCL</title>
    <updated>2020-12-11T23:14:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/ibvn1J8ipGklqO6fJS3-DA</id>
    <link href="https://mp.weixin.qq.com/s/ibvn1J8ipGklqO6fJS3-DA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020ASH好声音｜维布妥昔单抗(BV)联合利妥昔单抗、剂量调整CHP方案治疗75岁及以上DLBCL的初步研究</title>
    <updated>2020-12-10T19:01:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/tcjLZo8Q6BOcDmRX5ca7iA</id>
    <link href="https://mp.weixin.qq.com/s/tcjLZo8Q6BOcDmRX5ca7iA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>A+学院 | 冯晓勤教授：精益求精--PK指导下的血友病A个体化治疗</title>
    <updated>2020-12-10T19:01:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/7geJavhMyjx7j2ouN6CzqA</id>
    <link href="https://mp.weixin.qq.com/s/7geJavhMyjx7j2ouN6CzqA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田制药发布研发管线进展及其财务影响</title>
    <updated>2020-12-09T18:32:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/f3I_QUlxw6Sjy-6sOSBBjQ</id>
    <link href="https://mp.weixin.qq.com/s/f3I_QUlxw6Sjy-6sOSBBjQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田中国荣获“2020创新杰出贡献奖”</title>
    <updated>2020-12-09T18:32:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/WJaKM4LtHK7hIo36S7z_rQ</id>
    <link href="https://mp.weixin.qq.com/s/WJaKM4LtHK7hIo36S7z_rQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>武田抗巨细胞病毒药物phase III研究获得阳性结果</title>
    <updated>2020-12-08T22:15:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/3oqcYZHKalhVOF3wfEFZSA</id>
    <link href="https://mp.weixin.qq.com/s/3oqcYZHKalhVOF3wfEFZSA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020ASH好声音｜维布妥昔单抗联合纳武利尤单抗用于高危霍奇金淋巴瘤患者自体造血干细胞移植后巩固治疗</title>
    <updated>2020-12-08T22:15:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/cOrjFEDc9wKqDIx4bL2atQ</id>
    <link href="https://mp.weixin.qq.com/s/cOrjFEDc9wKqDIx4bL2atQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH好声音 | 傅卫军教授解读：TOURMALINE-MM4研究中伊沙佐米维持治疗对于不同MRD状态的NDMM患者的PFS获益</title>
    <updated>2020-12-08T22:15:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/iv2hFYn8bm92ZyHWoS754g</id>
    <link href="https://mp.weixin.qq.com/s/iv2hFYn8bm92ZyHWoS754g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>以患者为中心说到不如做到</title>
    <updated>2020-12-07T19:30:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/88BAB8QrPZkZr9KTmToKDQ</id>
    <link href="https://mp.weixin.qq.com/s/88BAB8QrPZkZr9KTmToKDQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH好声音 |【朱军教授点评】 ECHELON-1研究5年结果更新：BV联合化疗用于 III/IV期cHL患者的一线治疗</title>
    <updated>2020-12-07T19:30:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/wH6HM1-FFXns_y3cU0KHGg</id>
    <link href="https://mp.weixin.qq.com/s/wH6HM1-FFXns_y3cU0KHGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020ASH好声音｜MRD检测在多发性骨髓瘤中的应用进展</title>
    <updated>2020-12-07T19:30:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/xakNI7w7R7cwyHOwO1ILJw</id>
    <link href="https://mp.weixin.qq.com/s/xakNI7w7R7cwyHOwO1ILJw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>EGFR/HER2靶向药来那替尼（Niratinib）中文说明书</title>
    <updated>2020-12-07T19:30:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/VPdn-4jURwX_HJ1TLTb7uQ</id>
    <link href="https://mp.weixin.qq.com/s/VPdn-4jURwX_HJ1TLTb7uQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>华为涉足医药界</title>
    <updated>2020-12-06T21:15:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/wBdQkbohRJYZ2NuMMDYTKA</id>
    <link href="https://mp.weixin.qq.com/s/wBdQkbohRJYZ2NuMMDYTKA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020ASH好声音 | 熟悉的身影、全新的舞台：口服蛋白酶体抑制剂的新玩法</title>
    <updated>2020-12-06T21:15:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/dJytPLsB607qnGwKbLGuSg</id>
    <link href="https://mp.weixin.qq.com/s/dJytPLsB607qnGwKbLGuSg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020ASH好声音|陈文明教授：PI同类药物转换支持非移植骨髓瘤的持续治疗</title>
    <updated>2020-12-06T21:15:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/4lFjicltd-831yRzvBD6-A</id>
    <link href="https://mp.weixin.qq.com/s/4lFjicltd-831yRzvBD6-A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>遗传性血管性水肿（HAE）大合集</title>
    <updated>2020-12-05T10:27:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/nNlPQVZxbbcbNXbFQizikg</id>
    <link href="https://mp.weixin.qq.com/s/nNlPQVZxbbcbNXbFQizikg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020ASH好声音 | 复发难治多发性骨髓瘤最新研究详述（二）</title>
    <updated>2020-12-05T10:27:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/AHVzfpcM31Zo5TY_vKsk0A</id>
    <link href="https://mp.weixin.qq.com/s/AHVzfpcM31Zo5TY_vKsk0A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020ASH好声音 | B细胞淋巴瘤最新研究</title>
    <updated>2020-12-05T10:27:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-05:/s/BSCTMFL4C4P_DvcDz6mYLg</id>
    <link href="https://mp.weixin.qq.com/s/BSCTMFL4C4P_DvcDz6mYLg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>